Recent 8-K filings for MANE
Highest-materiality recent filing
Veradermics' VDPHL01 meets all primary and key secondary endpoints in Phase 2/3 male hair loss trial
- VDPHL01 achieved mean TAHC increase of 30.3 hairs/cm² (QD) and 33.0 hairs/cm² (BID) vs 7.3 for placebo at Month 6 (p<0.0001)
- 79.3% (QD) and 86.0% (BID) of patients reported improvement on AAIRS vs 35.6% placebo
-
Veradermics: Phase 2 VDPHL01 shows 22.7-23.3 hairs/cm² increase, 88.9-90% improved at Month 6
Mean non-vellus hair count increase of 22.7 hairs/cm² (once daily) and 23.3 hairs/cm² (twice daily) at Month 6.
-
Veradermics Q1 net loss $27.2M, positive Phase 2/3 results for VDPHL01 hair loss drug
Net loss $27.2M for Q1 2026 vs $12.4M Q1 2025; R&D $20.9M, G&A $8.9M.
-
Veradermics raises $414M in public offering and private placement to Suvretta Capital
Closed underwritten public offering of 3,843,790 shares at $100.00 per share, gross proceeds ~$384M.
-
Veradermics' VDPHL01 meets all primary and key secondary endpoints in Phase 2/3 male hair loss trial
VDPHL01 achieved mean TAHC increase of 30.3 hairs/cm² (QD) and 33.0 hairs/cm² (BID) vs 7.3 for placebo at Month 6 (p<0.0001)
-
Veradermics reports preliminary cash of $390.8M as of March 31, 2026
Preliminary unaudited cash, cash equivalents and marketable securities total approximately $390.8 million as of March 31, 2026.
-
FY 2025 net loss $70.0M vs $26.5M in 2024; Q4 net loss $21.8M vs $5.7M.
-
Veradermics files amended charter and bylaws after IPO closing on Feb 5, 2026
Authorized 200M shares of common stock and 25M shares of undesignated preferred stock.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.95 · Median 0.80 · Most common event other_material